BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), today announced the development of two new derivative cell lines from the Company’s patented PICM-19 liver stem cells for use in HepaLife’s first-of-its-kind bioartificial liver device currently under development for the treatment of human liver failure.